How genetic differences affect immune cell responses to antibody treatments
Impacts of genetic variation in the Fc gamma receptor locus on functionality of natural killer cells and monocytes
This study is looking at how differences in certain genes might affect how well antibody treatments work for people, especially in immune cells, so that doctors can create more personalized and effective therapies for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | North Carolina State University Raleigh NIH-funded |
| Lab location | 1 site (Raleigh, United States) |
| Project ID | NIH-11029532 on NIH RePORTER |
What this research studies
This research investigates how variations in genes related to Fc gamma receptors influence the effectiveness of antibody-based therapies in immune cells like natural killer cells and monocytes. By analyzing genetic differences, the study aims to understand why some patients respond better to these treatments than others. The researchers have developed a high-throughput assay to identify functional genetic variations that may impact immune responses. This could lead to more personalized and effective antibody therapies for various diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals undergoing antibody-based therapies for conditions such as infections, autoimmune disorders, or cancer.
Not a fit: Patients who do not receive antibody-based treatments or those with genetic profiles that do not affect Fc gamma receptor functionality may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved antibody treatments tailored to individual genetic profiles, enhancing treatment efficacy for patients.
How similar studies have performed: Previous research has shown that genetic variations can significantly impact treatment responses, suggesting that this approach has potential for success.
Where this research is happening
Raleigh, United States
- North Carolina State University Raleigh — Raleigh, United States (Active)
Researchers
- Principal investigator: Peng, Xinxia — North Carolina State University Raleigh
- Study coordinator: Peng, Xinxia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.